Publication date: May 08, 2019
This is a randomized, controlled, multi-center phase III clinical study to evaluate the efficacy and safety of JS001(Toripalimab Injection) combined with Axitinib as first-line therapy in patients with advanced mucosal melanoma. The target population are treatment-naive patients with histopathologically confirmed, unresectable stage III or stage IV mucosal melanoma. At randomization, the patients will be 1:1 randomized to two groups (73 subjects in each): the test group will receive Toripalimab Injection combined with Axitinib; the control group will receive Toripalimab Injection alone; when disease progression or intolerable toxicity occurs in a group, the treatment will be ended in that group while survival follow-up starts.
- An International Placebo-Controlled Comparative Randomized Trial of Efficacy and Safety of Sequential BCD-217 and BCD-100 Therapy Compared to BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic Melanoma
- Atezolizumab Combined With Intratumoral G100 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors